

RECEIVED
CENTRAL FAX CENTER

OCT 15 2008

CLAIMS

I claim:

Claims 1-4 (cancelled)

Claim 5 (previously presented) A disomic cell line derived from trisomic embryos.

Claim 6 (currently amended) A stem cell derived from said disomic cell [[lines]] line of claim 5.

Claim 7 (currently amended) [[A]] The method of producing disomic cell lines comprising the steps of:

- a) culturing trisomic embryos onto mouse feeder cells consisting of mouse embryonic fibroblast cells (ATCC-STO) said mouse embryonic fibroblast cells having been previously mitotically inactivated by mitomycin [[mitocimin]] C in gelatin-tissue culture dishes; and,
- b) maintaining said mouse feeder cells using maintenance medium comprising [[medium]] Dulbeccos's Modified Eagle Medium (DMEM) without sodium pyruvate, glucose 4500 mL-1 supplemented with 20% fetal bovine serum, 0.1 mM-mercaptoethanol, 1% non-essential amino acids, 1 mM L-glutamine, 50 units ml L-1 penicillin; and,
- c) supplementing said maintenance medium with human recombinant Leukemia Inhibitory factor at 2000 units mL-1 and bFGF 4ng/ml; and,
- d) culturing said embryos in said supplemented maintenance medium until day 12; and,
- e) fixing and analyzing by FISH said disomic [[embryonic]] cell lines; and,
- f) identifying and isolating disomic cell lines within said trisomic embryos wherein disomic cell lines are produced.

Claim 8 (currently amended) [[A]] The method of claim 7 wherein stem cell lines are isolated from said disomic cell lines.